CD8A and neoplasm: In later drug development, those imaging BMs could help to get a better understanding of pathophysiological/molecular resistance mechanisms such as PD-L1 expression, CD8+ cell exclusion, or functional exhaustion of immune cells impeding anti-tumor responses (15, 16).